PARP inhibitors are being developed as therapeutic brokers for most cancers. Greater than six compounds have entered scientific trials. The vast majority of these compounds are β-nicotinamide adenine dinucleotide (NAD(+))-competitive inhibitors. One exception is iniparib, which has been proposed to Read more…
Month: June 2021
Impaired DNA harm response pathways might create vulnerabilities of most cancers cells that may be exploited therapeutically. One such selective vulnerability is the sensitivity of BRCA1- or BRCA2-defective tumors (therefore faulty in DNA restore by homologous recombination, HR) to inhibitors Read more…
- Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
- Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
- An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
- Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.
- Targeted therapy for cancer using PARP inhibitors.